How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,092 results for

Depo Provera

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

221. Celecoxib After Tonsillectomy

and must use an acceptable method of contraception, including abstinence, a barrier method (diaphragm or condom), Depo-Provera, or an oral contraceptive, for the duration of the study. Parental/guardian permission (informed consent) and if appropriate, child assent. Exclusion Criteria: Prior adenotonsillar surgery. Concomitant surgical procedure that adds more than mild additional pain. Note: ear tubes are always permissible. Coagulation disorder, or any other hematologic disorder that affects clotting

2016 Clinical Trials

222. A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.

injections, combined pill, progestin-only pill, hormone-releasing transdermal patch or vaginal ring, and depot medroxyprogesterone acetate injection (Depo-Provera). Have one male sex partner who has had a vasectomy >/=3 months prior. Male partner with barrier protection plus the use of vaginal spermicide. Practice abstinence defined as refraining from heterosexual intercourse from 30 days before first vaccination until at least 60 days after last ZPIV vaccination. Female subjects must agree to not donate

2016 Clinical Trials

223. Making Healthy Decisions

intervention ] Number of partners with whom had vaginal, oral, or anal sex without using condoms or insertive condoms Number of sexual partners without using condoms [ Time Frame: 9 months post intervention ] Number of partners with whom had vaginal, oral, or anal sex without using condoms or insertive condoms Birth control use [ Time Frame: 3 months post intervention ] Use and consistency of use of 14 birth control methods (birth control pills, patch, Depo Provera, ring, IUD, implant, condoms, female (...) condoms, diaphragm, cervical cap, sponge, spermicide, "safe time of month," "pull out"), and emergency contraception Birth control use [ Time Frame: 9 months post intervention ] Use and consistency of use of 14 birth control methods (birth control pills, patch, Depo Provera, ring, IUD, implant, condoms, female condoms, diaphragm, cervical cap, sponge, spermicide, "safe time of month," "pull out"), and emergency contraception Nutrition knowledge [ Time Frame: 3 months post intervention ] Count

2016 Clinical Trials

224. A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation

kg/m2 and 30 kg/m2, inclusive, and must weigh more than 45 kg Male subjects must either have a vasectomy or agree that they and any female partners will use 2 acceptable forms of contraception, one of which must be a condom, until 30 days after the last dose of study drug. Other acceptable forms of contraception include hormonal contraceptives, intrauterine device, Depo Provera®, Norplant® System Implants, bilateral tubal ligation, bilateral oophorectomy, hysterectomy, and contraceptive sponge

2016 Clinical Trials

225. Nicotine Receptor Density & Response to Nicotine Patch: Pt 2 Extended Treatment

reliable method of birth control during the trial (e.g., birth control pills, Depo-Provera, and/or condoms with spermicide). Must be clinically stable (i.e., no inpatient hospitalizations for 3 months prior to enrollment, no changes in medication in the four weeks prior to enrollment) Exclusion Criteria: current or past history of cardiovascular disease including myocardial infarction, acute coronary syndrome, angina pectoris, coronary artery disease, atrial fibrillation/flutter, cor pulmonale

2016 Clinical Trials

226. A Study to Investigate the Effect of a Nitric Oxide Supplementation on Pre- and Mildly Hypertensive Adults

), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) Double-barrier method Non-hormonal intrauterine devices Vasectomy of partner BMI 18.5-29.9 kg/m2 (±1 kg/m2) Seated resting systolic blood pressures between 130-150 mmHg (inclusive) and diastolic blood pressure ≤ 100 mmHg at screening visit Agreement to maintain current level of physical activity and diet throughout the study Agrees to comply with study procedures including

2016 Clinical Trials

227. Effect of Hypoglycemia on Sleep

by the investigator after reviewing the subjects activity level) Current use of an insulin pump. Willingness to follow all study procedures, including attending all clinic visits. Willingness to sign informed consent and HIPAA documents. Exclusion Criteria: Female of childbearing potential who is pregnant or intending to become pregnant or breast-feeding, or is not using adequate contraceptive methods. Acceptable contraception includes birth control pill / patch / vaginal ring, Depo-Provera, Norplant

2016 Clinical Trials

228. TR-987 vs. Placebo Following Fractionated CO2 Laser Resurfacing of the Chest

/implants Norplant®, Depo-Provera®, double-barrier methods (e.g. condoms and spermicide), abstinence and vasectomies of partner with a documented second acceptable method of birth control should the subject become sexually active]. All systemic birth control measures must be in consistent use at least 30 days prior to study participation. Postmenopausal is defined as having the last menstrual cycle in at least 12 months Negative urine pregnancy test results at the time of study entry (if applicable (...) , nursing an infant or planning a pregnancy during the study [throughout the course of the study, women of child-bearing potential must use reliable forms of contraception (i.e., oral contraceptive, contraceptive patches/rings/implants Norplant®, Depo-Provera®, double-barrier methods (e.g. condoms and spermicide), abstinence, or vasectomies of partner with a documented second acceptable method of birth control should the subject become sexually active]. Current participation or participation within 30

2016 Clinical Trials

229. Endometriosis

choice. Advise the woman to start a 3–month trial of a conventional regimen, then switch to tricycling or continuous use if this does not control symptoms. Oral (desogestrel 75 micrograms), depot (Depo-Provera ® or SAYANA PRESS ® ), subdermal implant (Nexplanon ® ), and intrauterine progestogen-only (Mirena ® ) contraceptives may also be considered, after a full discussion of the advantages and disadvantages. See the CKS topics on , , and for detailed information on prescribing hormonal (...) Reproduction and Embryology (ESHRE) guideline Management of women with endometriosis [ ]. Progestogen-only pill (Cerazette ® ) — CKS found no studies assessing the effectiveness of Cerazette ® for endometriosis, and the recommendation to offer it is a pragmatic approach as a Cochrane review found no overall of benefit of oral progestagens over other medical treatments [ ]. Depot medroxyprogesterone acetate (Depo-Provera ® or SAYANA PRESS ® ) — this recommendation is based on expert opinion from CKS

2014 NICE Clinical Knowledge Summaries

230. A Study Investigating the Effects of Niagenâ„¢ in Healthy Adults.

, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) Double-barrier method Non-hormonal intrauterine devices Vasectomy of partner Healthy as determined by laboratory results, medical history, and physical exam Agrees to comply with study procedure Agrees to maintain current level of physical activity throughout the study and avoid exercising on the day of study visits 3 to 7 (prior

2016 Clinical Trials

231. Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib

salpingectomy but not tubal ligation Females of child-bearing potential should use reliable methods of contraception from the time of screening until 3 months after discontinuing osimertinib. Acceptable methods of contraception include total and true sexual abstinence, tubal ligation, hormonal contraceptives that are not prone to drug-drug interactions (IUS Levonorgestrel Intra Uterine System (Mirena), Medroxyprogesterone injections (Depo-Provera), copper-banded intra-uterine devices, and vasectomized

2016 Clinical Trials

232. Single and Multiple Ascending Doses Clinical Pharmacology Study With KAR5585

but becomes active during study participation, the subject agrees they and their partner will use a medically accepted form of contraception for the time specified. Medically acceptable forms of contraception are: FDA-approved female hormonal contraceptives used consistently for 2 or more cycles before Screening, including oral contraceptives, intrauterine device (IUD), medroxyprogesterone acetate injection (Depo Provera®), hormonal implant (Norplant®, Implanon®, Nexplanon®), and vaginal ring (NuvaRing®

2016 Clinical Trials

233. Exploratory Study of Efficacy and Safety of Ingenol Mebutate 0.05% Gel for Common Warts on the Hands.

medically acceptable methods of birth control: Oral Contraceptives, Contraceptive patches, Contraceptive Injection (Depo-Provera®), Contraceptive Implant (Implanon™), Essure®, Vaginal Contraceptive (Nuva-Ring®), IUD, hormonal IUD (Mirena®); double-barrier methods (e.g. condom and spermicide), sterile partner (e.g., vasectomy performed at least six months prior to the subject's initiation of treatment) and abstinence with a documented second acceptable method of birth control should subject become

2016 Clinical Trials

234. Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults

: abstinence, condoms (male or female with or without a spermicide), diaphragm or cervical cap with spermicide, intrauterine device, contraceptive pills or patch, Norplant, Depo-Provera or other FDA approved contraceptive method, or male partner has previously undergone a vasectomy as declared in medical history. EXCLUSION CRITERIA: Any subject who meets any of the following criteria will not qualify for entry into the study: History of prior infection with a filovirus or prior participation in a filovirus

2016 Clinical Trials

235. Prebiotic in Preventing Low Birth Weight

unwilling to comply with study protocol (x) Presence of UTI or bacteriuria in a morning mid stream fresh urine sample (xi) Presence of abnormal vaginal flora (Nugent score >7) (xii) History of irregular bleeding due to injectable Depo-Provera Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its

2016 Clinical Trials

236. Polyphenol/Prebiotic Blend Effects on GI Health and Microbial Composition

20-60 years of age Female subjects of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result. Acceptable methods of birth control include: Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) Double-barrier methods Non-hormonal intrauterine devices

2016 Clinical Trials

237. Long-Acting Progestin Contraception and the Vaginal Microbiome

: Observational Actual Enrollment : 28 participants Observational Model: Cohort Time Perspective: Prospective Official Title: Impact of Long-Acting Progestin Contraception on the Vaginal Microbiome Study Start Date : March 2016 Actual Primary Completion Date : June 1, 2018 Actual Study Completion Date : June 1, 2018 Resource links provided by the National Library of Medicine related topics: Groups and Cohorts Go to Group/Cohort Depo Provera Ten women ages 18-40 who elect to start a using Depo Provera (...) . If the hypothesis of a vaginal microbial shift with Depo Provera (DMPA) use is confirmed (our PRIMARY analysis), these tools will enable visualization of the differences. The tables of relative abundance of either taxonomic groups or metabolic pathways will be used to identify differential bacterial biomarkers present among patient and sample classes. Two bioinformatics tools particularly useful for biomarker discovery are LEfSe and MaAsLin (Multivariate Association with Linear Models, http

2016 Clinical Trials

238. LARC Forward Contraceptive Counseling at MHCC

are FDA approved. During the study participants will undergo counseling to choose the method of birth control that is right for them. This will include watching an informational video and having a discussion with study staff. If participants choose pills, the patch the ring, or a diaphragm and do not have any contraindications to this method, they will receive a prescription for this method to be filled at the pharmacy of their choice. If participants choose Depo-Provera (the shot), they will receive

2016 Clinical Trials

239. Efficacy of a LRCâ„¢ (L. Reuteri NCIMB 30242) Capsule on Managing Cholesterol in Adults

year since last menstruation) OR Female subject of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result. Acceptable methods of birth control include Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System); Intrauterine devices; Vasectomy of partner

2016 Clinical Trials

240. Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection

, including abstinence, a barrier method (diaphragm or condom), Depo-Provera, or hormonal contraceptive (oral, implant, ring, patch) for the duration of the study. (NOTE: The subject must have used the chosen method of birth control for at least 1 month/cycle prior to enrollment into the study). Exclusion Criteria: Subjects who received antibiotics within the last 14 days Visible evidence of compromised skin integrity is present at the catheter exit site or evidence of a catheter exit site infection

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>